Trials / Completed
CompletedNCT04441450
ADME Study of [14C]ICP-022 in Healthy Males
Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled ICP-022: An Open-Label, Phase I, Single-Dose Study in Healthy Males
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the absorption, the metabolic pathways and the excretion of ICP-022 in healthy male adult participants after administration of a single oral dose of 150 mg of 14C ICP-022.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]ICP-022 | 150mg suspension containing 100μCi of \[14C\]ICP-022 |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2019-08-06
- Completion
- 2019-08-06
- First posted
- 2020-06-22
- Last updated
- 2020-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04441450. Inclusion in this directory is not an endorsement.